ASTRAZENECA PLC-SPONS ADR (AZN)

Is AstraZeneca Stock a Buy?

AstraZeneca PLC Announcement: If You Have Suffered Losses in AstraZeneca PLC (NASDAQ: AZN), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche

Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments.

Rosen Law Firm Encourages AstraZeneca PLC Investors to Inquire About Securities Class Action Investigation - AZN

/PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...

Rosen Law Firm Encourages AstraZeneca PLC Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – AZN

Did AstraZeneca PLC Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - AZN

AZN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your AstraZeneca PLC investment

AstraZeneca PLC (AZN) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

3 Unstoppable Stocks to Buy Right Now

Shareholders that lost money on AstraZeneca PLC(AZN) should contact Levi & Korsinsky about Securities Fraud Investigation - AZN

AstraZeneca PLC INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by AstraZeneca PLC (AZN)

Levi & Korsinsky Investigates Possible Securities Fraud Violations by AstraZeneca PLC (AZN)

LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial

Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer

2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer

Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial

March 2025 Options Now Available For AstraZeneca (AZN)

IMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancer

IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors

Nasdaq 100 Movers: MDLZ, MRVL

The Law Offices of Frank R. Cruz Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN). Such investors...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN). Such investors...

TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial

Interesting AZN Call Options For January 2025

3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now